EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Prevalence of metabolic dysfunction-associated steatotic liver disease among obese, overweight, and at-risk children and adolescents in Türkiye: A meta-analysis

Eda Kaya, Caglayan Keklikkiran, Mehlika Toy, Yusuf Yilmaz

Hepatology Forum · 2026 · 7 (4) · 361-373

DOI: 10.14744/hf.2026.88519 ↗
AbstractBibliografische Angaben

Abstract

Background and Aim: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly non-alcoholic fatty liver disease (NAFLD), is the most common chronic liver disease worldwide. Among children, the overall prevalence of MASLD is estimated at around 7%, and early manifestation is associated with a more severe prognosis. Despite this growing burden, no systematic analysis of pediatric MASLD prevalence in Türkiye has yet been conducted. Here, we aimed to estimate the pediatric MASLD prevalence among children with specific conditions in Türkiye. Materials and Methods: A comprehensive literature search was conducted for studies published in English and/or Turkish between 2005 and 2023 using the databases MED-LINE, PubMed, EMBASE, and ULAKBIM. The search strategy included the following terms: “Türkiye AND NAFLD AND Pediatric” and “Türkiye AND NAFLD AND Prevalence AND Chil-dren AND Adolescent.” The studies identified through this literature review were incor-porated into the meta-analysis, which included either obese/overweight or at-risk chil-dren or adolescents with specific conditions such as increased transaminases. Results: The pooled overall prevalence of MASLD was estimated as 44.6% (95% confi-dence interval [CI]: 39.5–49.7) among at-risk children and adolescents. Heterogeneity among studies was considerable, with an I2 value of 96%, indicating substantial variabil-ity. Subgroup analysis showed a pooled prevalence of 54.9% in boys (95% CI: 48.6–61.1) and 41.2% in girls (95% CI: 35.6–46.9). Regionally, the prevalence was 49.0% (95% CI: 41.2–57.1) in the Marmara and Aegean regions, and 42.2% (95% CI: 35.3–49.1) in the Black Sea, Mediterranean, and Central Anatolian regions. Conclusion: The results of this study indicate a markedly high prevalence of MASLD among at-risk children and adolescents. These findings should serve as an alert for policymakers to adapt healthcare strategies aimed at preventing childhood obesity and MASLD.Materials and Methods: A comprehensive literature search was conducted for studies published in English and/or Turkish between 2005 and 2023 using the databases MEDLINE, PubMed, EMBASE, and UlakBim. The search strategy included the following terms: “Türkiye AND NAFLD AND Pediatric” and “Türkiye AND NAFLD AND Prevalence AND Children AND Adolescent.” The studies identified through this literature review were incorporated into the meta-analysis, which included either obese/overweight or at-risk children or adolescents with specific conditions such as increased transaminases. Results: The pooled overall prevalence of MASLD was estimated as 44.6% (95% confidence intervals [CI]: 39.5–49.7) among at-risk children and adolescents. Heterogeneity among studies was considerable, with an I2 value of 96%, indicating substantial variability. Subgroup analysis showed a pooled prevalence of 54.9% in boys (95% CI: 48.6–61.1) and 41.2% in girls (95% CI: 35.6–46.9). Regionally, the prevalence was 49.0% (95% CI: 41.2–57.1) in the Marmara and Aegean regions, and 42.2% (95% CI: 35.3–49.1) in the Black Sea, Mediterranean, and Central Anatolian regions. Conclusion: The results of this study indicate a markedly high prevalence of MASLD among at-risk children and adolescents. These findings should serve as an alert for policymakers to adapt healthcare strategies aimed at preventing childhood obesity and MASLD.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →